Heather Sevinsky

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. doi request reprint The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women
    Heather Sevinsky
    Research and Development, Bristol Myers Squibb, Princeton, NJ, USA
    Antivir Ther 16:149-56. 2011
  2. doi request reprint Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
    Marc Bifano
    Research and Development, Bristol Myers Squibb, Hopewell, NJ, USA
    Antivir Ther 19:511-9. 2014
  3. doi request reprint The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus
    Timothy Eley
    Research and Development, Bristol Myers Squibb, P O Box 4000, Princeton, NJ, 08543 4000, USA
    Clin Drug Investig 34:661-71. 2014
  4. doi request reprint Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study
    Li Zhu
    Bristol Myers Squibb, Research and Development, Princeton, NJ, USA
    J Antimicrob Chemother 67:465-8. 2012
  5. doi request reprint Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir
    Marc Bifano
    Bristol Myers Squibb Research and Development, Hopewell, NJ, USA
    Antivir Ther 18:931-40. 2013

Collaborators

  • Timothy Eley
  • Jenny Zhang
  • Jean Michel Molina
  • Marc Bifano
  • Richard Bertz
  • Hamza Kandoussi
  • Dennis Grasela
  • Carey Hwang
  • Li Zhu
  • Hao Jiang
  • Maria Velinova-Donga
  • Berend Oosterhuis
  • Jan Hartstra
  • Renger Tiessen
  • Donnie McGrath
  • Awny Farajallah
  • Anna Persson
  • Michael Child
  • Xiaohui Xu
  • Mark Krystal
  • Shanmei Liao

Detail Information

Publications5

  1. doi request reprint The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women
    Heather Sevinsky
    Research and Development, Bristol Myers Squibb, Princeton, NJ, USA
    Antivir Ther 16:149-56. 2011
    ..Women of childbearing age represent a growing proportion of people living with HIV. Preventing pregnancy is important in HIV-infected women receiving efavirenz as part of their antiretroviral therapy...
  2. doi request reprint Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
    Marc Bifano
    Research and Development, Bristol Myers Squibb, Hopewell, NJ, USA
    Antivir Ther 19:511-9. 2014
    ..The primary objective of this study was to assess the effect of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate (Ortho Tri-Cyclen(®))...
  3. doi request reprint The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus
    Timothy Eley
    Research and Development, Bristol Myers Squibb, P O Box 4000, Princeton, NJ, 08543 4000, USA
    Clin Drug Investig 34:661-71. 2014
    ..The combination of direct-acting antiviral agents in patients with chronic hepatitis C virus (HCV) infection has demonstrated clinical benefit; however, evaluation of potential drug-drug interactions is required prior to therapy...
  4. doi request reprint Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study
    Li Zhu
    Bristol Myers Squibb, Research and Development, Princeton, NJ, USA
    J Antimicrob Chemother 67:465-8. 2012
    ..To characterize the pharmacokinetics and inhibitory quotient (IQ) of atazanavir/ritonavir- and lopinavir/ritonavir-based regimens in HIV-infected, treatment-naive patients...
  5. doi request reprint Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir
    Marc Bifano
    Bristol Myers Squibb Research and Development, Hopewell, NJ, USA
    Antivir Ther 18:931-40. 2013
    ..With the advent of direct-acting antivirals (DAAs) for HCV, potential drug interactions between antiretrovirals and DAAs require evaluation prior to co-therapy...